| Title |
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
|
|---|---|
| Published in |
OncoTargets and therapy, August 2017
|
| DOI | 10.2147/ott.s103532 |
| Pubmed ID | |
| Authors |
Sheel A Patel, Jean Hoffman-Censits |
| Abstract |
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are now multiple effective and approved agents for this disease state. The optimal sequencing of these agents is unclear as there are no large-scale head-to-head comparisons. Clinicians must familiarize themselves with the most recent studies as well as drug toxicities to determine the best treatment option for their patients. In this review, we focus on the development of cabazitaxel for mCRPC, evaluate its efficacy, and highlight key strategies for toxicity management. Additionally, we summarize the studies that address cabazitaxel treatment sequencing and optimal dosing schedule. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 14% |
| Student > Bachelor | 3 | 11% |
| Student > Postgraduate | 3 | 11% |
| Researcher | 2 | 7% |
| Student > Master | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 13 | 46% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 11% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Arts and Humanities | 1 | 4% |
| Immunology and Microbiology | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 14 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 March 2021.
All research outputs
#8,045,790
of 25,604,262 outputs
Outputs from OncoTargets and therapy
#436
of 3,012 outputs
Outputs of similar age
#117,180
of 328,070 outputs
Outputs of similar age from OncoTargets and therapy
#9
of 83 outputs
Altmetric has tracked 25,604,262 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,012 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,070 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.